A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for ...

Novo Nordisk (NVO) closed the most recent trading day at $84.03, moving -1.36% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.47% for the day.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.